Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — Shareholder Meeting (May 2021)
24 slides from Vita Life Sciences's shareholder meeting presentation, May 28, 2021
Slide 1: Annual General Meeting
ANNUAL GENERAL MEETING FOR THE YEAR ENDED 31 DECEMBER 2020 herbsofgold AVTETFETS 1
Slide 2: Agenda
AGENDA 1. CHAIRMAN’S WELCOME ADDRESS ) 2. MANAGING DIRECTOR’S REVIEW 3. ORDINARY RESOLUTIONS 4. QUESTION & ANSWER WAYVITA LIFE
Slide 3: Chairman Mr Townsing profile
Mr Townsing brings over 30 years’ experience in corporate finance and private equity. He was a Director of the Company, from 1985 to 1992, 2004 to 2009 and was reappointed a Director on 22"¢ December 2011. Mr Townsing was appointed as the Chairman of the Company effective 28" May 2021 and is also th
Slide 4: Managing Director's Review
MANAGING DIRECTOR’S REVIEW bari ANDREW O'KEEFE mawacinc pirector Mr O'Keefe was appointed Managing Director on 1" January 2017. Mr O'Keefe has over 20 years’ experience within the Australian pharmaceutical and healthcare industry. During his career Mr O'Keefe has held senior leadership positions in
Slide 5: Management team
—- ANDREW O'KEEFE SHAUN RUTHERFORD MELISSA PEREIRA MANAGING DIRECTOR GLOBAL SALES DIRECTOR IFAD OF MARKETING GER, MALAYSIA ©. Sy | ( RENEE TI SUAT LING KOAY ALEXANDRA WAR! s JORPORATE MANAGER NEW PRODUCT IT MANAG WY VITA LIFE a
Slide 6: Company history and mission
distribution of high cede foming rai supplements across the Asia Pacific region * Conduct activities it in a socially responsi + Create a conductive working environm + Provide competitive returns on shareholi jers’ investment HISTORY 1947 1974 2000 2002 VitaHealth was first Launched VitaHealth Vita
Slide 7: Children's Health
Children’s Health Nutritionals Weight Management Pain & Inflammation Hair, Skin & Nails Women’s Health WAVITA LIFE | GENERAL MEETING 28 MAY 2021 | FOR THE YEAR ENDED 31 DECEMBER 2020 7
Slide 8: Herbs of Gold
herbsofgold WY VITA LIFE ANNUAL GENERAL MEETING 28 MAY 2021 | FOR THE YEAR ENDED 31 DECEMBER 2020 8
Slide 9: Strategic plan to stimulate sales
3 years ago the business implemented a strategic plan to stimulate sales after consistent periods of stagnant growth ered over 1 stomers and 5m with an growth rate of 5.7% o\ the past four years GENERAL MEET! ENDED 31D
Slide 10: Key Financial Insights
KEY FINANCIAL INSIGHTS Pre-Tax Profit Sales Gm) sm) “ 50 8 45 7 6 40 5 ll ii | 3 }' 30 2017 2018 2019 2020 Higher marketing investment was 2020 required a deliberate Higher sales combined with Record group sales required in 2018/2019 to support our _ strategy toreduce normalised lower operating cost
Slide 11: 2020 Highlights
2020 HIGHLIGHTS ¥ Record Group sales of $46.5m, an increase of 9.5% on PCP ¥ New distribution channels delivered record sales performance across key markets in Australia and Malaysia ¥ Immunity products supporting consumers health and wellbeing during COVID -19 stimulated category performance ¥ New
Slide 12: 2020 Revenue by Geography
2020 Revenue by Geography Other Asia 9% Singapore Australia 10% 45% Asia | 55% | x Malaysia 36% TOTAL REVENUE: $46.5M 2019 Revenue by Geography Other Asia 10%, Singapore 14% Malaysia “We 37% TOTAL REVENUE: $42.4M WASTE
Slide 13: Brand building and talent wellbeing
Brand building ion Talent wellbeing Group investment ro roup investment on strategy to drive dr q y talent acquisition to consumer & retailer a support growth engagement ‘sting expe ANNUAL GENERAL MEET!
Slide 14: Outlook & Guidance
OUTLOOK & GUIDANCE The impact of Covid 19 remains a fluid situation, which may disrupt traditional selling channels Management remains confident to deliver first half growth First Half FY 2021 sales of around, $23.5m - $24.5m (H1 2020: $22.0m) First Half FY 2021 EBIT of around, $4.0m - $4.5m (H1 202
Slide 15: Annual Year 2020
: a SE. ANNUAL GENERAL MEETING 28 MAY 2021 | FOR THE YEAR ENDED 31 DECEMBER 2020
Slide 16: Ordinary Resolutions
ORDINARY RESOLUTIONS 1. REMUNERATION REPORT 2. RE-ELECTION OF DIRECTOR - MR GREGORY RALPH 3. INCREASE IN NON-EXECUTIVE DIRECTOR AGGREGATE REMUNERATION 4. SHARE BUY BACK 5. LONG TERM INCENTIVE PLAN SHARES-MANAGING DIRECTOR ERENT A VITA LIFE ANNUAL GENERAL MEETING 28 MAY 2021 | FOR THE YEAR ENDED 31 D
Slide 17: Proxy Resolution: Remuneration Report
PROXY-RESOLUTION 1 PROXY’S RESOLUTIONS IN FAVOUR AGAINST DISCRETION EXCLUDED a) Adoption of the Remuneration Report 25,959,006 52,478 4,181 9,846,013 GENERAL MEETING 28 MAY y 3 WAVITA LIFE
Slide 18: Proxy Resolution: Re-election of Director
PROXY-RESOLUTION 2 PROXY’S RESOLUTIONS IN FAVOUR AGAINST DISCRETION EXCLUDED 2) Re-election of Director (Mr Gregory Ralph) 35,837,497 20,000 4,181 ie} - WY VITA LIFE GENERAL MEETING 28 MAY 2021 | FOR THE YE MAS CVENCES 48
Slide 19: Proxy Resolution: Non-Executive Director Remuneration
PROXY-RESOLUTION 3 PROXY’S RESOLUTIONS IN FAVOUR AGAINST DISCRETION EXCLUDED 3) Increase in Aggregate Remuneration of 24,430,546 33,521 4,181 11,393,430 Non-Executive Directors GENERAL MEETING 28 MAY y WAVITA LIFE 7
Slide 20: Proxy Resolution: Share buy-back
PROXY-RESOLUTION 4 PROXY’S RESOLUTIONS IN FAVOUR AGAINST DISCRETION EXCLUDED 4) Share buy-back 35,857,497 io} 4,181 ie} WY VITA LIFE ENERAL MEETING 28 MAY 2021 | F MASCIENTES 99
Slide 21: Proxy Resolution: Long Term Investment Plan Shares
PROXY-RESOLUTION 5 PROXY’S RESOLUTIONS IN FAVOUR AGAINST DISCRETION EXCLUDED 5) Long Term Investment Plan Shares 24,402,036 67,021 4,181 11,388,440 - Managing Director GENERAL MEETING 28 MAY y NAVITA LIFE a
Slide 22: Proxy
PROXY PROXY’S RESOLUTIONS IN FAVOUR AGAINST DISCRETION EXCLUDED ) Adoption of the Remuneration Report 25,959,006 52,478 4,181 9,846,013 2) Re-election of Director (Mr Gregory Ralph) 35,837,497 20,000 4,181 ie} 3) Increase in Aggregate Remuneration of 24,430,546 33,521 4,181 11,393,430 Non-Executive
Slide 23: L YEAR
L GENERAL MEETING 28 MAY 2021 | FOR THE YEAR ENDED 31 DECEMBER 2
Slide 24: Thank You
THANK YOU DISCLAIMER: This document has been prepared y Vite Life Sciences Limited (Vita Life Sciences) and comprises written material/slides for a presentation ring Vita Life Sciences. The presentation is for information purposé not constitute nor form part of invitation to a or otherw of, or issue